Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-Blind, Placebo-controlled, Randomized Study Evaluating the Efficacy, Safety, and Tolerability of Sage-324 in the Treatment of Individuals With Essential Tremor

NCT04305275 is registered in ClinicalTrials.gov with Sage Therapeutics as lead sponsor.

NCT NCT04305275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04305275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-Blind, Placebo-controlled, Randomized Study Evaluating the Efficacy, Safety, and Tolerability of Sage-324 in the Treatment of Individuals With Essential Tremor
Lead sponsor
Sage Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
May 19, 2020
Completion date
February 15, 2021
Enrollment
69 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

essential tremor